全球克氏综合征治疗市场 – 行业趋势和 2030 年预测

克氏综合征治疗市场分析和规模

根据美国国家人类基因组研究所的记录，每 500-1,000 名新生男婴中约有 1 人患有克氏综合征。据美国国家人类研究所的研究人员称，由于男性患者中克氏综合征的症状和体征难以识别，因此很难诊断。目前尚无确定的治疗方法，但可根据患者的症状进行治疗。治疗包括心理社会问题、男性乳房发育和性腺功能低下等。

Data Bridge Market Research 分析了 2023-2030 年预测期内全球克氏综合征治疗市场的增长率。在上述预测期内，全球克氏综合征治疗市场的预期复合年增长率趋于 4.46% 左右。2022 年市场价值为 10.8 亿美元，到 2030 年将增长至 15.4 亿美元。除了市场价值、增长率、细分市场、地理覆盖范围、市场参与者和市场情景等市场洞察外，Data Bridge Market Research 团队策划的市场报告还包括深入的专家分析、患者流行病学、渠道分析、定价分析和监管框架。

克氏综合征治疗市场范围和细分

Market Definition

Klinefelter syndrome, also known as 47, XXY, is a genetic disorder where you have an extra X chromosome. This common chromosome disorder affects around one in five hundred people. Many people with Klinefelter syndrome never get diagnosed, though. The symptoms vary differently among patients, but few have no apparent signs of the disease. This syndrome may cause reduced muscle mass, body and facial hair, and enlarged breast tissue.

Global Klinefelter Syndrome Treatment Market Dynamics

Drivers

• Increasing prevalence of Klinefelter syndrome

Klinefelter syndrome is considered the most common type of human sex chromosome disorder. It occurs in around 1 in every 500 to 1,000 males. Furthermore, every year, over 3,000 boys are born in the U.S. with this syndrome. This contributes to the growth of the market.

• The growing change of changing lifestyles

The trending changing lifestyles of the people, leading to the increase in pregnancy rate after age 35, surges the risk of occurrence of Klinefelter syndrome. This would create demand for its treatment, helping drive the Klinefelter syndrome treatment market.

Opportunities

• Increase in the number of product approvals       

The increased in focus of Klinefelter syndrome treatment market players on the development of newer products for the treatment of Klinefelter syndrome and major product approvals in the past few years have boosted the market's growth. For instance, in March 2019, Clarus Therapeutics received U.S. FDA approval for Jatenzo, an oral testosterone capsule that would help treat hypogonadism in Klinefelter syndrome patients. Furthermore, in April 2019, the U.S. FDA approved the marketing of a generic testosterone gel 1.62% developed by Lupin. This would help as a replacement therapy for men having hypogonadism.

• The emergence of new varied treatments

The new evolving research organizations in the market are equipped with and utilize the knowledge of professionals in numerous clinical disciplines, leading to important advances in understanding Klinefelter-related disorders and treatment. For instance, Testosterone replacement therapy can also help with bone density, fracture prevention, and mood and behavior. It also corrects androgen deficiency, promoting body proportion normalization and the development of normal male secondary sex characteristics.

Restraints/Challenges

• Limited treatment options

Not all males with XXY conditions can be benefitted from testosterone therapy. For instance, the benefits of taking testosterone for men whose testosterone levels are low to normal are less clear than for those whose testosterone levels are extremely low. Additionally, all possible side effects are acne, skin rashes from patches or gels, breathing issues, and an increased risk of an enlarged prostate gland or prostate cancer as you get older. Thus, this factor acts as a major hindrance to market growth.

• High cost of treatment

The huge expenditure required for the treatment processes hampers the market growth. Numerous market players make huge investments in developing new and advanced treatment procedures to faster the recovery process, and in return, the cost is increased.

This global Klinefelter syndrome treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global Klinefelter syndrome treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Klinefelter Syndrome Treatment Market

COVID-19 infection was common in 10% of Klinefelter syndrome patients. The presence of an extra X chromosome in all infected patients leads to mild symptoms as the presence of an extra X chromosome influences a better clinical outcome. The development of infection was not protected by testicular atrophy. SARS-CoV-2 infection was majorly associated with the presence of one affected cohabitant. The link between SARS-CoV-2 and hypogonadism was confirmed, but the formulation of the TRT was unimportant. Therefore, COVID-19 is expected to impact market growth positively.

Global Klinefelter Syndrome Treatment Market Scope

The global klinefelter syndrome treatment market is segmented on the basis of treatment, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Testosterone Replacement Therapy
• Fertility Treatment
• Surgeries
• Hormone Treatment
• Others

End-Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Klinefelter Syndrome Treatment Market Regional Analysis/Insights

对全球克氏综合征治疗市场进行了分析，并按治疗、分销渠道和最终用户提供了市场规模洞察和趋势。

全球克氏综合征治疗市场报告涵盖的主要国家 包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于该地区发展中国家的睾酮产量不断增长，北美将在预测期内占据市场主导地位。

随着人们对克氏综合征的认识不断加深，亚太地区预计未来几年将实现增长。

报告的国家部分还提供了影响市场当前和未来趋势的各个市场影响因素和国内市场监管变化。此外，在提供国家数据预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈竞争或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和全球克氏综合征治疗市场份额分析

全球克氏综合征治疗市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对全球克氏综合征治疗市场的关注有关

全球克氏综合征治疗市场的主要参与者包括：

• 霍夫曼-罗氏有限公司（瑞士）
• 武田药品工业株式会社 (日本)
• 协和麒麟株式会社（日本）
• 辉瑞公司 (美国)
• 阿斯利康（英国）
• Abbvie, Inc.（美国）
• Bausch Health Companies Inc.（美国）。
• 百时美施贵宝公司 (美国)
• 葛兰素史克公司 (GSK Plc.)（美国
•  Mylan NV（美国）
• 诺华公司（瑞士）
• 阿斯利康（英国）  

SKU-56244